A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients

Autor: Asbjørn Due, Tobias Berg, Maj-Britt Jensen, Sophie Yammeni, Lone Volmer, Anne Sofie Brems-Eskildsen, Klaus Kaae Andersen, Saeeda Rana, Ann Knoop, Iben Kümler

Publikováno v: Due, A, Berg, T, Jensen, M-B, Yammeni, S, Volmer, L, Brems-Eskildsen, A S, Andersen, K K, Rana, S, Knoop, A & Kümler, I 2023, ' A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients ', Acta Oncologica, vol. 62, no. 2, pp. 126-133 . https://doi.org/10.1080/0284186X.2023.2176257

Background: Current guidelines in HER2-positive metastatic breast cancer (mBC) recommend the combination of trastuzumab and a chemotherapeutic agent for 3rd line or later treatments. This study aims to describe the treatment of HER2-positive mBC in 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6fdae1238291c95b8c578fd876afeb8

The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

Autor: T. Dongsgaard, Sven Tyge Langkjer, Lars Stenbygaard, Helle Lemvig Kruse, Julia Kenholm, Anne Sofie Brems-Eskildsen, Jeanette Dupont Jensen, Hella Danø, Bjørnar Gilje, Kim Wedervang, J. Neimann, Jürgen Geisler, Erik Hugger Jacobsen, Vesna Glavicic, Mie Grunnet, Annette Torbøl Brixen

Publikováno v: Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : A direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2019, ' The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer ', Future Oncology, vol. 15, no. 22, pp. 2561-2569 . https://doi.org/10.2217/fon-2019-0124

Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd3e68144dbea7113137cab419868c36
http://hdl.handle.net/10852/77735

Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer

Autor: Niels Fristrup, Anne Sofie Brems-Eskildsen, Claus Rödel, Jørgen Bjerggaard Jensen, Benedicte Parm Ulhøi, Rainer Fietkau, Michael Wittlinger, Arndt Hartmann, Simone Bertz, Jens R. Laurberg, Iver Nordentoft, Troels Schepeler, Michael Borre, Lars Dyrskjøt, Mads Agerbæk, Torben F. Ørntoft

Publikováno v: BJU International. 110:E1228-E1236

What's known on the subject? and What does the study add? Several studies have shown that defects in DNA-damage response are associated with good survival after chemotherapy and radiotherapy. Furthermore, loss of cell cycle regulators may be prognost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a0f5234328008429d882ae9fe1f9e1a3
https://doi.org/10.1111/j.1464-410x.2012.11564.x

The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer

Autor: E. H. Jacobsen, Annette Torbøl Brixen, Lars Stenbygaard, H.L. Kruse, J. Neimann, Julia Kenholm, M. Grunnet, Jürgen Geisler, Anne Sofie Brems-Eskildsen, K. Wedervang, Sven Tyge Langkjer, Jeanette Dupont Jensen, Vesna Glavicic, T. Dongsgaard, Hella Danø

Publikováno v: Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Danø, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2018, ' The NAME trial : A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer ', Annals of Oncology, vol. 29, no. Suppl. 8, 366TiP, pp. viii120 . https://doi.org/10.1093/annonc/mdy272.354
Langkjer, S T, Kenholm, J, Jensen, J D, Wedervang, K, Brixen, A T, Grunnet, M, Stenbygaard, L, Dano, H, Glavicic, V, Jacobsen, E H, Brems-Eskildsen, A S, Kruse, H L, Dongsgaard, T, Neimann, J & Geisler, J 2018, ' The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer ', Annals of Oncology, vol. 29, no. Suppl. 8, pp. viii120 . https://doi.org/10.1093/annonc/mdy272.354

Background: Navebine is an antineplastic agent that has shown afficacy in the treatment of a variety of solid tumors, including breast cancer. The drug can be given intriavenously, but also as oral tablet treatment. Preclinical studies, as well as cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575b48a23ba570b0569b579d24d75308
https://doi.org/10.1093/annonc/mdy272.354

A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models

Autor: Bjarne Kuno Møller, Anja Bille Bohn, Thomas Nielsen, Lotte Bonde Bertelsen, Michael R. Horsman, Thomas Wittenborn, Tinne Laurberg, Anne Sofie Brems-Eskildsen, Hans Stødkilde-Jørgensen

Publikováno v: PLoS ONE
Bohn, A B, Wittenborn, T, Brems-Eskildsen, A S, Laurberg, T, Bertelsen, L B, Nielsen, T, Stødkilde-Jørgensen, H, Møller, B K & Horsman, M R 2014, ' A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models ', PLOS ONE, vol. 9, no. 10, pp. e110091 . https://doi.org/10.1371/journal.pone.0110091
PLoS ONE, Vol 9, Iss 10, p e110091 (2014)

The vascular disrupting agent combretastatin A-4 disodium phosphate (CA4P) induces fluctuations in peripheral blood neutrophil concentration. Because neutrophils have the potential to induce both vascular damage and angiogenesis we analyzed neutrophi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c88c503c0d02f389b42cfbf39193b8
https://pubmed.ncbi.nlm.nih.gov/25299269